Dr. Nnamdi Edokobi counsels biotechnology and life sciences companies on the development, protection, and strategic management of intellectual property assets. His practice focuses on patent preparation and prosecution, global portfolio development, and intellectual property strategy for emerging and established therapeutic platforms. Nnamdi works closely with inventors, in-house counsel, and business stakeholders to develop patent strategies aligned with scientific, clinical, and commercial objectives. He has experience supporting intellectual property portfolios on a variety of therapeutic areas, including, biologics, nucleic acid therapeutics, gene therapy, genome editing, protein engineering, and related technologies. His work spans all stages of portfolio development, from early-stage invention harvesting and patent drafting through global prosecution, portfolio expansion, and lifecycle management. Prior to entering patent practice, Nnamdi earned his PhD in Pharmacology from the University of Michigan, where his research focused on the molecular and physiological consequences of genetic variation in neurological and cardiovascular disease. His work investigated neuronal and cardiac function, through the use of molecular, biochemical, and electrophysiological approaches, in animal and stem cell models of developmental pediatric epilepsy. Publications and Presentations “Sodium channel β1 subunits participate in regulated intramembrane proteolysis-excitation coupling,” co-author, JCI Insight, January 2021 “Scn1b deletion results in sinoatrial node dysfunction, atrial remodeling, and increased susceptibility to atrial fibrillation in neonates.,” presenter, Annual Meeting of the American Epilepsy Society, December 2020 “Sodium channel β1 subunits are post-translationally modified by tyrosine phosphorylation, S-palmitoylation, and regulated intramembrane proteolysis,” co-author, Journal of Biological Chemistry, June 2020 “Characterizing SUDEP Biomarkers in SCN1B-linked Developmental and Epileptic Encephalopathy (DEE) Patient-Derived Cardiac Myocytes,” presenter, Annual Meeting of the American Epilepsy Society, December 2019 “Characterizing Sudden Unexpected Death in Epilepsy Biomarker in Dravet Syndrome Patient-Derived Cardiac Myocytes,” presenter, Cardiac Arrhythmia Mechanisms Gordon Research Conference, March 2019 “Voltage-Gated Sodium Channel β1/β1B Subunits Regulate Cardiac Physiology and Pathophysiology,” first author, Frontiers in Physiology, April 2018 “RANKL/RANK control Brca1 mutation-driven mammary tumors,” co-author, Cell Research “Examining the RANK-L Inhibitor as a Potential Targeted Therapy in Brca1 mutant mice,” presenter, Annual Meeting of the American Association for Cancer Research Education & Credentials University of Michigan, PhD (2021) Pharmacology University of Maryland, Baltimore County, BS (2015) Biochemistry and Molecular Biology